|
|||||
|
 | |
| |
| |
| |
| |
| |
|
Gene: DUSP9 |
Gene summary for DUSP9 |
 Gene summary. |
| Gene information | Species | Human | Gene symbol | DUSP9 | Gene ID | 1852 |
| Gene name | dual specificity phosphatase 9 | |
| Gene Alias | MKP-4 | |
| Cytomap | Xq28 | |
| Gene Type | protein-coding | GO ID | GO:0000165 | UniProtAcc | Q6P9C2 |
Top |
Malignant transformation analysis |
| Identification of the aberrant gene expression in precancerous and cancerous lesions by comparing the gene expression of stem-like cells in diseased tissues with normal stem cells |
| Malignant transformation involving gene list. |
| Entrez ID | Symbol | Replicates | Species | Organ | Tissue | Adj P-value | Log2FC | Malignancy |
| 1852 | DUSP9 | P2T-E | Human | Esophagus | ESCC | 1.76e-12 | 2.64e-01 | 0.1177 |
| 1852 | DUSP9 | P4T-E | Human | Esophagus | ESCC | 3.48e-08 | 2.22e-01 | 0.1323 |
| 1852 | DUSP9 | P5T-E | Human | Esophagus | ESCC | 3.97e-04 | 1.20e-01 | 0.1327 |
| 1852 | DUSP9 | P9T-E | Human | Esophagus | ESCC | 3.05e-03 | 1.42e-01 | 0.1131 |
| 1852 | DUSP9 | P10T-E | Human | Esophagus | ESCC | 9.44e-07 | 2.31e-01 | 0.116 |
| 1852 | DUSP9 | P15T-E | Human | Esophagus | ESCC | 2.13e-05 | 1.52e-01 | 0.1149 |
| 1852 | DUSP9 | P16T-E | Human | Esophagus | ESCC | 8.84e-05 | 1.50e-01 | 0.1153 |
| 1852 | DUSP9 | P21T-E | Human | Esophagus | ESCC | 4.17e-05 | 1.44e-01 | 0.1617 |
| 1852 | DUSP9 | P22T-E | Human | Esophagus | ESCC | 4.31e-06 | 1.36e-01 | 0.1236 |
| 1852 | DUSP9 | P24T-E | Human | Esophagus | ESCC | 3.50e-02 | 1.06e-01 | 0.1287 |
| 1852 | DUSP9 | P26T-E | Human | Esophagus | ESCC | 6.56e-15 | 3.02e-01 | 0.1276 |
| 1852 | DUSP9 | P28T-E | Human | Esophagus | ESCC | 5.17e-27 | 5.53e-01 | 0.1149 |
| 1852 | DUSP9 | P32T-E | Human | Esophagus | ESCC | 3.75e-03 | 9.52e-02 | 0.1666 |
| 1852 | DUSP9 | P36T-E | Human | Esophagus | ESCC | 1.55e-04 | 1.98e-01 | 0.1187 |
| 1852 | DUSP9 | P37T-E | Human | Esophagus | ESCC | 1.03e-11 | 2.56e-01 | 0.1371 |
| 1852 | DUSP9 | P38T-E | Human | Esophagus | ESCC | 5.18e-03 | 1.60e-01 | 0.127 |
| 1852 | DUSP9 | P44T-E | Human | Esophagus | ESCC | 6.93e-04 | 1.56e-01 | 0.1096 |
| 1852 | DUSP9 | P47T-E | Human | Esophagus | ESCC | 8.40e-04 | 1.23e-01 | 0.1067 |
| 1852 | DUSP9 | P49T-E | Human | Esophagus | ESCC | 4.64e-06 | 4.34e-01 | 0.1768 |
| 1852 | DUSP9 | P74T-E | Human | Esophagus | ESCC | 1.96e-03 | 1.40e-01 | 0.1479 |
| Page: 1 2 3 |
| Transcriptomic changes along malignancy continuum. |
| Tissue | Expression Dynamics | Abbreviation |
| Esophagus |  | ESCC: Esophageal squamous cell carcinoma |
| HGIN: High-grade intraepithelial neoplasias | ||
| LGIN: Low-grade intraepithelial neoplasias | ||
| Liver |  | HCC: Hepatocellular carcinoma |
| NAFLD: Non-alcoholic fatty liver disease | ||
| Oral Cavity |  | EOLP: Erosive Oral lichen planus |
| LP: leukoplakia | ||
| NEOLP: Non-erosive oral lichen planus | ||
| OSCC: Oral squamous cell carcinoma |
| ∗log2FC in expression of this searched gene in stem-like cells from each diseased tissue sample relative to stem-like cells in normal samples in each tissue plotted against the malignancy continuum. Samples are colored based on if they are from different disease stage. |
Top |
Malignant transformation related pathway analysis |
| Find out the enriched GO biological processes and KEGG pathways involved in transition from healthy to precancer to cancer |
| Figure of enriched GO biological processes. |
| Tissue | Disease Stage | Enriched GO biological Processes |
| Colorectum | AD |  |
| Colorectum | SER |  |
| Colorectum | MSS |  |
| Colorectum | MSI-H |  |
| Colorectum | FAP |  |
| ∗Top 15 enriched GO BP terms are showed in the bar plot of each disease state in each tissue. Each row represents a significant GO biological process which is colored according to the -log10(p.adjust). |
| Page: 1 2 3 4 5 6 7 8 9 |
| Enriched GO biological processes. |
| GO ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | Count |
| GO:003109818 | Esophagus | ESCC | stress-activated protein kinase signaling cascade | 154/8552 | 247/18723 | 8.53e-08 | 1.44e-06 | 154 |
| GO:005140318 | Esophagus | ESCC | stress-activated MAPK cascade | 147/8552 | 239/18723 | 5.43e-07 | 7.18e-06 | 147 |
| GO:00072549 | Esophagus | ESCC | JNK cascade | 102/8552 | 167/18723 | 4.22e-05 | 3.39e-04 | 102 |
| GO:0043409110 | Esophagus | ESCC | negative regulation of MAPK cascade | 105/8552 | 180/18723 | 4.13e-04 | 2.35e-03 | 105 |
| GO:003109822 | Liver | HCC | stress-activated protein kinase signaling cascade | 138/7958 | 247/18723 | 1.43e-05 | 1.57e-04 | 138 |
| GO:005140322 | Liver | HCC | stress-activated MAPK cascade | 134/7958 | 239/18723 | 1.50e-05 | 1.64e-04 | 134 |
| GO:00434097 | Liver | HCC | negative regulation of MAPK cascade | 98/7958 | 180/18723 | 7.88e-04 | 4.74e-03 | 98 |
| GO:000725412 | Liver | HCC | JNK cascade | 89/7958 | 167/18723 | 3.09e-03 | 1.44e-02 | 89 |
| GO:003109816 | Oral cavity | OSCC | stress-activated protein kinase signaling cascade | 141/7305 | 247/18723 | 5.74e-09 | 1.25e-07 | 141 |
| GO:005140316 | Oral cavity | OSCC | stress-activated MAPK cascade | 134/7305 | 239/18723 | 6.02e-08 | 1.09e-06 | 134 |
| GO:004340917 | Oral cavity | OSCC | negative regulation of MAPK cascade | 105/7305 | 180/18723 | 1.10e-07 | 1.87e-06 | 105 |
| GO:00072548 | Oral cavity | OSCC | JNK cascade | 90/7305 | 167/18723 | 6.49e-05 | 5.26e-04 | 90 |
| GO:00703735 | Oral cavity | OSCC | negative regulation of ERK1 and ERK2 cascade | 43/7305 | 78/18723 | 2.80e-03 | 1.22e-02 | 43 |
| GO:00703716 | Oral cavity | OSCC | ERK1 and ERK2 cascade | 150/7305 | 330/18723 | 9.47e-03 | 3.38e-02 | 150 |
| GO:00703724 | Oral cavity | OSCC | regulation of ERK1 and ERK2 cascade | 140/7305 | 309/18723 | 1.34e-02 | 4.46e-02 | 140 |
| GO:003109817 | Oral cavity | LP | stress-activated protein kinase signaling cascade | 88/4623 | 247/18723 | 7.39e-05 | 9.68e-04 | 88 |
| GO:004340918 | Oral cavity | LP | negative regulation of MAPK cascade | 67/4623 | 180/18723 | 1.18e-04 | 1.40e-03 | 67 |
| GO:005140317 | Oral cavity | LP | stress-activated MAPK cascade | 84/4623 | 239/18723 | 1.79e-04 | 2.00e-03 | 84 |
| Page: 1 |
| Enriched KEGG pathways. |
| Pathway ID | Tissue | Disease Stage | Description | Gene Ratio | Bg Ratio | pvalue | p.adjust | qvalue | Count |
| hsa0401014 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| hsa0401015 | Oral cavity | OSCC | MAPK signaling pathway | 165/3704 | 302/8465 | 7.11e-05 | 2.74e-04 | 1.40e-04 | 165 |
| Page: 1 |
Top |
Cell-cell communication analysis |
| Identification of potential cell-cell interactions between two cell types and their ligand-receptor pairs for different disease states |
| Ligand | Receptor | LRpair | Pathway | Tissue | Disease Stage |
| Page: 1 |
Top |
Single-cell gene regulatory network inference analysis |
| Find out the significant the regulons (TFs) and the target genes of each regulon across cell types for different disease states |
| TF | Cell Type | Tissue | Disease Stage | Target Gene | RSS | Regulon Activity |
| ∗The dot plots of a searched regulon are shown for all cell subpopulations in each disease state of each tissue based on the regulon specific score inferred using pySCENIC and by calculating the average expression. |
| Page: 1 |
Top |
Somatic mutation of malignant transformation related genes |
| Annotation of somatic variants for genes involved in malignant transformation |
| Hugo Symbol | Variant Class | Variant Classification | dbSNP RS | HGVSc | HGVSp | HGVSp Short | SWISSPROT | BIOTYPE | SIFT | PolyPhen | Tumor Sample Barcode | Tissue | Histology | Sex | Age | Stage | Therapy Types | Drugs | Outcome |
| DUSP9 | SNV | Missense_Mutation | c.997T>A | p.Phe333Ile | p.F333I | Q99956 | protein_coding | deleterious(0) | probably_damaging(0.995) | TCGA-A2-A04R-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | taxol | SD | |
| DUSP9 | SNV | Missense_Mutation | c.1057N>A | p.Glu353Lys | p.E353K | Q99956 | protein_coding | tolerated(0.53) | benign(0.001) | TCGA-A2-A0YK-01 | Breast | breast invasive carcinoma | Female | <65 | I/II | Chemotherapy | cytoxan | SD | |
| DUSP9 | SNV | Missense_Mutation | novel | c.943N>C | p.Asp315His | p.D315H | Q99956 | protein_coding | deleterious(0) | probably_damaging(0.998) | TCGA-C5-A8YR-01 | Cervix | cervical & endocervical cancer | Female | <65 | I/II | Unknown | Unknown | PD |
| DUSP9 | SNV | Missense_Mutation | novel | c.1091N>G | p.Ser364Cys | p.S364C | Q99956 | protein_coding | deleterious(0.03) | possibly_damaging(0.785) | TCGA-HM-A4S6-01 | Cervix | cervical & endocervical cancer | Female | <65 | III/IV | Chemotherapy | cisplatin | CR |
| DUSP9 | SNV | Missense_Mutation | rs781805190 | c.541N>A | p.Asp181Asn | p.D181N | Q99956 | protein_coding | tolerated(0.11) | possibly_damaging(0.707) | TCGA-AA-3821-01 | Colorectum | colon adenocarcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| DUSP9 | SNV | Missense_Mutation | novel | c.825N>A | p.Phe275Leu | p.F275L | Q99956 | protein_coding | deleterious(0) | probably_damaging(0.968) | TCGA-AA-3984-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DUSP9 | SNV | Missense_Mutation | c.1103N>A | p.Ser368Tyr | p.S368Y | Q99956 | protein_coding | tolerated(0.08) | possibly_damaging(0.837) | TCGA-D5-6534-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD | |
| DUSP9 | SNV | Missense_Mutation | c.38N>A | p.Arg13Gln | p.R13Q | Q99956 | protein_coding | tolerated(0.27) | benign(0) | TCGA-D5-6930-01 | Colorectum | colon adenocarcinoma | Male | >=65 | I/II | Unknown | Unknown | SD | |
| DUSP9 | SNV | Missense_Mutation | rs782644901 | c.475G>A | p.Val159Met | p.V159M | Q99956 | protein_coding | tolerated(0.06) | benign(0.372) | TCGA-G4-6588-01 | Colorectum | colon adenocarcinoma | Female | <65 | I/II | Unknown | Unknown | SD |
| DUSP9 | SNV | Missense_Mutation | rs782495643 | c.598C>T | p.Arg200Trp | p.R200W | Q99956 | protein_coding | deleterious(0.03) | possibly_damaging(0.462) | TCGA-A5-A0G1-01 | Endometrium | uterine corpus endometrioid carcinoma | Female | >=65 | I/II | Unknown | Unknown | SD |
| Page: 1 2 3 4 |
Top |
Related drugs of malignant transformation related genes |
| Identification of chemicals and drugs interact with genes involved in malignant transfromation |
| (DGIdb 4.0) |
| Entrez ID | Symbol | Category | Interaction Types | Drug Claim Name | Drug Name | PMIDs |
| Page: 1 |
Copyright 2023-Present -The University of Texas Health Science Center at Houston |